Resource use and economic impact of patients with gout: A multicenter, population-wide study;Uso de recursos e impacto económico de los pacientes con gota: Estudio multicéntrico de ámbito poblacional

Reumatologia Clinica

Volumn 9, Issue 2, 2013, Pages 94-100

  Sicras Mainar, Antoni ^a   Navarro Artieda, Ruth ^b   Ibáñez Nolla, Jordi ^a  

^a Badalona Serveis Assistencials SA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cost; Gout; Metabolic syndrome; Resources use

Indexed keywords

ARTICLE; COMORBIDITY; DIABETIC PATIENT; FEMALE; FOLLOW UP; GOUT; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORBIDITY; MULTICENTER STUDY; OUTPATIENT CARE; PREVALENCE; PRIMARY HEALTH CARE; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; COST OF ILLNESS; FEMALE; FOLLOW-UP STUDIES; GOUT; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RETROSPECTIVE STUDIES; SPAIN; YOUNG ADULT;

EID: 84875378838     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2012.06.014     Document Type: Article

References (31)

1. Lai S.W., Liu C.S., Lin T., Lin C.C., Lai H.C., Liao K.F. Prevalence of gout and hyperuricemia in Taiwan: a hospital-based, cross-sectional study. South Med J 2009, 102:772-773.
2. So A. Epidemiology: gout-bad for the heart as well as the joint. Nat Rev Rheumatol 2010, 6:386-387.
3. Hamburger M., Baraf H.S., Adamson T.C., Basile J., Bass L., Cole B., et al. European League Against Rheumatism. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med 2011, 123:3-36.
4. Wallace S.L., Robinson H., Masi A.T., Decker J.L., McCarty D.J., Yu T.F. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20:895-900.
5. Zhang W., Doherty M., Bardin T., Pacual E., Barskova V., Conagham P., et al. EULAR Evidence based recommendations for gout Part II. Management. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
6. Janssens H.J., Janssen M., van de Lisdonk E.H., Fransen J., van Riel P.L., van Weel C. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis 2010, 69:1255-1256.
7. Perez-Ruiz F., Pascual E., Carmona L., Gonzalez-Gay M.A., De Miguel E., Ureña I., et al. Diagnosis of gout in the rheumatology, hospital-based setting lies far from that recommended: results from the GEMA (Gout Evaluation of Management) Study. Arthritis Rheum 2007, 56:S639.
8. Schumacher H.R, Edwards L.N., Perez-Ruiz F., Becker M., Chen L.X., Furst D.E., et al. Outcome measures for acute and chronic gout. J Rheumatol 2005, 32:2452-2455. OMERACT 7 Special Interest Group.
9. Ferroni P., Basili S., Paoletti V., Davi G. Endothelial dysfunction and oxidative stress in arterial hypertension. Nutr Metab Cardiovasc Dis 2006, 16:222-233.
10. Shah A., Keenan R.T. Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?. Curr Rheumatol Rep 2010, 12:118-124.
11. Hjortnaes J., Algra A., Olijhoek J., Huisman M., Jacobs J., van der Graaf Y., et al. Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome. J Rheumatol 2007, 34:1882-1887.
12. Choi H.K., Ford E.S., Li C., Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007, 57:109-115.
13. Onat A., Uyarel H., Hergenç G., Karabulut A., Albayrak S., Sari I., et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 2006, 19:1055-1062.
14. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program-Expert Panel on Detection, Evaluation, Treatment on High Blood Cholesterol in Adults (Adult Treatment Panel III).
15. Singh J.A. Health care costs in gout: what are these emerging data telling us?. J Clin Rheumatol 2009, 15:1-2.
16. Wu E.Q., Patel P.A., Yu A.P., Mody R.R., Cahill K.E., Tang J., Krishnan E. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm 2008, 14:164-175.
17. Kim K.Y., Ralph Schumacher H., Hunsche E., Wertheimer A.I., Kong S.X. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003, 25:1593-1617.
18. Wu E.Q., Patel P.A., Mody R.R., Yu A.P., Cahill K.E., Tang J., et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?. J Rheumatol 2009, 36:1032-1040.
19. Mould-Quevedo J., Peláez-Ballestas I., Vázquez-Mellado J., Terán-Estrada L., Esquivel-Valerio J., Ventura-Ríos L., et al. El costo de las principales enfermedades reumáticas inflamatorias desde la perspectiva del paciente en México. Gac Méd Méx 2008, 144:225-231.
20. Ferraz M.B., O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995, 22:908-914.
21. Brook R.A., Kleinman N.L., Patel P.A., Melkonian A.K., Brizee T.J., Smeeding J.E., et al. The economic burden of gout on an employed population. Curr Med Res Opin 2006, 22:1381-1389.
22. The International Classification of Primary Care in the European Community. With a multi-language layer 1993, Oxford University Press, Oxford. H. Lamberts, M. Wood, I.M. Hofmans-Okkes (Eds.).
23. Ministerio de Sanidad, Servicios Sociales e Igualdad. Portal estadístico del SNS 2010. Clasificación Internacional de Enfermedades, novena revisión, Modificación Clínica (CIE-9-MC) [accedido diciembre 2011]. Disponible en: http://www.msc.es/estadEstudios/estadisticas/normalizacion/clasifEnferm/home.htm.
24. Charlson M.E., Pompei P., Ales K.L., Mackenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
25. Weiner J.P., Starfield B.H., Steinwachs D.M., Mumford L.M. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care 1991, 29:452-472.
26. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108:414-419.
27. Instituto Nacional de Estadística 2010. Encuesta de costes laborales del año 2010 [accedido diciembre 2011]. Disponible en: http://www.ine.es/infoine.
28. Thompson S.G., Barber J.A. How should cost data in pragmatic randomised trials be analysed?. BMJ 2000, 320:1197-1200.
29. Fraile J.M., García Puig J. Síndrome metabólico, hiperuricemia y gota. Rev Esp Obes 2009, 7:85-90.
30. Halpern R., Mody R.R., Fuldeore M.J., Patel P.A., Mikuls T.R. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin 2009, 25:1711-1719.
31. Joish V.N., Donaldson G., Stockdale W., Oderda G.M., Crawley J., Sasane R., et al. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database. Curr Med Res Opin 2005, 21:535-544.